Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors

Michael S Hughes¹, Grazia Aleppo², Lia Bally³, Annanda Fernandes Moura B Batista⁴, Sue A Brown^{4

5}, Eileen R Faulds⁶, Linda A Gonder-Frederick⁴, Diana Isaacs⁷, Anna R Kahkoska^{8

9

10}, Jacob Ortega¹¹, William H Polonsky^{12

13}, Meaghan M Stumpf^{4

5}

Affiliations

¹ Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University, Stanford, CA, USA.
² Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³ Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
⁴ Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
⁵ Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
⁶ College of Nursing, The Ohio State University, Columbus, OH, USA.
⁷ Diabetes Center, Cleveland Clinic, Cleveland, OH, USA.
⁸ Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
⁹ Division of Endocrinology and Metabolism, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁰ Center for Aging and Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹¹ School of Osteopathic Medicine, Campbell University, Lillington, NC, USA.
¹² Behavioral Diabetes Institute, San Diego, CA, USA.
¹³ University of California San Diego, San Diego, CA, USA.

PMID: 39564761
PMCID: PMC11577555
DOI: 10.1177/19322968241296853

Review

Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors

Michael S Hughes et al. J Diabetes Sci Technol. 2025 Jan.

. 2025 Jan;19(1):34-46.

doi: 10.1177/19322968241296853. Epub 2024 Nov 20.

Authors

Affiliations

¹ Division of Endocrinology, Gerontology and Metabolism, Department of Medicine, Stanford University, Stanford, CA, USA.
² Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
³ Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
⁴ Center for Diabetes Technology, University of Virginia, Charlottesville, VA, USA.
⁵ Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
⁶ College of Nursing, The Ohio State University, Columbus, OH, USA.
⁷ Diabetes Center, Cleveland Clinic, Cleveland, OH, USA.
⁸ Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
⁹ Division of Endocrinology and Metabolism, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹⁰ Center for Aging and Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
¹¹ School of Osteopathic Medicine, Campbell University, Lillington, NC, USA.
¹² Behavioral Diabetes Institute, San Diego, CA, USA.
¹³ University of California San Diego, San Diego, CA, USA.

PMID: 39564761
PMCID: PMC11577555
DOI: 10.1177/19322968241296853

Abstract

As diabetes technologies continue to advance, their use is expanding beyond type 1 diabetes to include populations with type 2 diabetes, older adults, pregnant individuals, those with psychiatric conditions, and hospitalized patients. This review examines the psychosocial outcomes of these technologies across these diverse groups, with a focus on treatment satisfaction, quality of life, and self-management behaviors. Despite demonstrated benefits in glycemic outcomes, the adoption and sustained use of these technologies face unique challenges in each population. By highlighting existing research and identifying gaps, this review seeks to emphasize the need for targeted studies and tailored support strategies to understand and optimize psychosocial outcomes and well-being.

Keywords: diabetes and mental health; diabetes in pregnancy; inpatient diabetes management; older adults with diabetes; psychosocial impacts of diabetes technology; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MSH has consulted for Dexcom and has received research support through his institution from Insulet, Medtronic, and Tandem. GA has received consultant fees from Dexcom and Insulet and research support through her employer, Northwestern University, from Bayer, Fractyl Health, Insulet, MannKind, and Tandem Diabetes. LB has received product and research support for investigator-initiated studies from Dexcom and Ypsomed, in addition to speaker honoraria from Dexcom and Ypsomed. SAB has received grant support through her institution from Dexcom, Insulet, Roche Diagnostics, Tandem Diabetes Care, and Tolerion and has participated on a DSMB for MannKind. ERF has received grant support from Dexcom and Insulet and has served as a consultant for Dexcom. DI has been a speaker for Abbott Diabetes Care, Dexcom, Eli Lilly, and MannKind Corporation and has consulted for Eli Lilly, Insulet Corporation, Medtronic, and Novo Nordisk. In partnership with the University of Virginia, LAG-F manages fees for licenses for use of the Hypoglycemia Fear Survey (HFS-II) by for-profit organizations, with part of these fees used to support ongoing research and education related to fear of hypoglycemia in people with diabetes and their families. WHP has served as a consultant for Insulet. MMS has received grant support through her institution from Dexcom, Tandem, and Insulet.

References

1. Hughes MS, Addala A, Buckingham B. Digital technology for diabetes. N Engl J Med. 2023;389(22):2076-2086. doi:10.1056/NEJMra2215899. - DOI - PubMed
1. Galindo RJ, Ramos C, Cardona S, et al.. Efficacy of a smart insulin pen cap for the management of patients with uncontrolled type 2 diabetes: a randomized cross-over trial. J Diabetes Sci Technol. 2023;17(1):201-207. doi:10.1177/19322968211033837. - DOI - PMC - PubMed
1. Daly AB, Boughton CK, Nwokolo M, et al.. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med. 2023;29(1):203-208. doi:10.1038/s41591-022-02144-z. - DOI - PMC - PubMed
1. American Diabetes Association Professional Practice Committee 7. Diabetes technology: standards of care in diabetes—2024. Diabetes Care. 2024;47(suppl 1):S126-s44. doi:10.2337/dc24-S007. - DOI - PMC - PubMed
1. Christensen MB, Serifovski N, Herz AMH, et al.. Efficacy of bolus calculation and advanced carbohydrate counting in type 2 diabetes: a randomized clinical trial. Diabetes Technol Ther. 2020;23(2):95-103. doi:10.1089/dia.2020.0276. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors

Affiliations

Diabetes Technology Use in Special Populations: A Narrative Review of Psychosocial Factors

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources